MARGetuximab Or Trastuzumab (MARGOT)
Public ClinicalTrials.gov record NCT04425018. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
MARGetuximab Or Trastuzumab (MARGOT): A Phase II Study Comparing Neoadjuvant Paclitaxel/Margetuximab/Pertuzumab to Paclitaxel/Trastuzumab/Pertuzumab in Patients With Stage II-III HER2-positive Breast Cancer
Study identification
- NCT ID
- NCT04425018
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Enrollment
- 174 participants
Conditions and interventions
Interventions
- Margetuximab Drug
- Paclitaxel Drug
- Pertuzumab Drug
- Trastuzumab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Not listed
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 12, 2020
- Primary completion
- Oct 23, 2024
- Completion
- Jun 30, 2027
- Last update posted
- Nov 17, 2025
2020 – 2027
United States locations
- U.S. sites
- 14
- U.S. states
- 6
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Georgetown University Medical Center | Washington D.C. | District of Columbia | 20007 | — |
| MedStar Washington Hospital Center | Washington D.C. | District of Columbia | 20010 | — |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Dana-Farber Brigham Cancer Center - Foxborough | Foxborough | Massachusetts | 02035 | — |
| Dana-Farber at Milford | Milford | Massachusetts | 01757 | — |
| Dana-Farber at South Shore Hospital | Weymouth | Massachusetts | 02190 | — |
| Montefiore Medical Center | The Bronx | New York | 10461 | — |
| UPMC Hillman Cancer Center - Arnold Palmer at Mountain View | Greensburg | Pennsylvania | 15601 | — |
| UPMC Hillman Cancer Center - Arnold Palmer at Norwin | Irwin | Pennsylvania | 15642 | — |
| University of Pittsburgh Medical Center | Pittsburgh | Pennsylvania | 15213 | — |
| Baylor College of Medicine Medical Center | Houston | Texas | 77030 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| University of Washington Fred Hutchinson Cancer Care | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04425018, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 17, 2025 · Synced Apr 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04425018 live on ClinicalTrials.gov.